Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. - Wikidata - awgldk - TriplyDB

Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines.

Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines.

http://www.wikidata.org/entity/Q36810589

about

Cognitive training interventions for dementia and mild cognitive impairment in Parkinson’s Disease Aiming for Study Comparability in Parkinson's Disease: Proposal for a Modular Set of Biomarker Assessments to be Used in Longitudinal Studies Pathophysiology of Motor Dysfunction in Parkinson's Disease as the Rationale for Drug Treatment and Rehabilitation Structural Neuroimaging Markers of Cognitive Decline in Parkinson's Disease Quantitative EEG and Cognitive Decline in Parkinson's Disease Cognitive training in Parkinson disease: A systematic review and meta-analysis Neuroimaging studies of striatum in cognition part II: Parkinson's disease Parkinsonian syndromes Mild cognitive impairment in Parkinson's disease Can the DSM-5 framework enhance the diagnosis of MCI?What light have resting state fMRI studies shed on cognition and mood in Parkinson's disease?Gray and White Matter Contributions to Cognitive Frontostriatal Deficits in Non-Demented Parkinson's Disease Parkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies.The Impact of Physical Activity on Non-Motor Symptoms in Parkinson's Disease: A Systematic Review Cognitive Training in Parkinson's Disease: A Review of Studies from 2000 to 2014 Rational pharmacological approaches for cognitive dysfunction and depression in Parkinson's disease Precompetitive Data Sharing as a Catalyst to Address Unmet Needs in Parkinson's Disease Parkinson Disease and Dementia.Diagnostic Accuracy and Confidence in the Clinical Detection of Cognitive Impairment in Early-Stage Parkinson Disease.Treatment of psychosis and dementia in Parkinson's disease.Post-cueing deficits with maintained cueing benefits in patients with Parkinson's disease dementia.Emotional processing in Parkinson's disease and schizophrenia: evidence for response bias deficits in PD Evaluation of mild cognitive impairment subtypes in Parkinson's disease.People with Parkinson's disease and normal MMSE score have a broad range of cognitive performance Mini mental Parkinson test: standardization and normative data on an Italian sample.Neuroimaging of brain changes associated with cognitive impairment in Parkinson's disease.The Penn Parkinson's Daily Activities Questionnaire-15: Psychometric properties of a brief assessment of cognitive instrumental activities of daily living in Parkinson's disease Hallucinations and conscious access to visual inputs in Parkinson's disease Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis Tracking Parkinson's: Study Design and Baseline Patient Data.Orthostatic hypotension and cognitive impairment in Parkinson's disease: Causation or association?Modified serpinA1 as risk marker for Parkinson's disease dementia: Analysis of baseline data.Verbal memory declines more in female patients with Parkinson's disease: the importance of gender-corrected normative data.Biomarkers for dementia and mild cognitive impairment in Parkinson's disease.The ReSPonD trial--rivastigmine to stabilise gait in Parkinson's disease a phase II, randomised, double blind, placebo controlled trial to evaluate the effect of rivastigmine on gait in patients with Parkinson's disease who have fallen.A Comparative Study of Tower of London Scoring Systems and Normative Data.Clinical practice with anti-dementia drugs: A revised (third) consensus statement from the British Association for Psychopharmacology.The Mental Status Examination in Patients With Suspected Dementia.Lewy Body Dementias: Dementia With Lewy Bodies and Parkinson Disease Dementia Potential biomarkers relating pathological proteins, neuroinflammatory factors and free radicals in PD patients with cognitive impairment: a cross-sectional study

P2860

Q24188194-F1F9D465-05DD-4233-BA93-93E6E98C21ED Q24658443-74BF69EA-2C9E-4E07-8C2C-2D5B63D7A439 Q26745654-FF8554BB-9B3C-40E2-A789-58508ABECC6B Q26748709-6DAA7732-3EC7-4EF0-AA85-9E46D4380973 Q26752409-3D74CFA1-B019-4CEA-890A-8B1448CB716F Q26777668-8000572C-74F9-4F9E-8DB2-E95D4A380A75 Q26779306-A17ACC06-6CA1-41CC-B1D5-218E9573D111 Q27007524-BFBDB8C5-5BBB-4B79-978A-E95AFE013643 Q27007766-6FFD8507-E7F5-4DFC-AD4E-6A83ECBAE09C Q27026677-37D871E8-58BD-4F1F-867E-BCC5820C18D9 Q27321077-A12C9D4F-A0D6-4C5A-9E69-CCC3226C18C0 Q27327538-153616DD-9420-407F-A5A0-8A47004F9C51 Q27686837-F639C706-3051-40E0-A03C-FD3CE3DC301B Q28070324-E2CBB24A-EC4F-4AAC-B849-D71263A694A8 Q28073680-43DF50B5-335F-41CA-B41E-C8274D7E37D0 Q28084380-2BCF9695-62C6-41C8-A26D-ADD501726CDA Q28601965-C3EB9E08-2704-465F-AD02-C4985552E0ED Q30248574-6725EB45-ED48-4EC1-BC55-F218162A1C09 Q30252794-3273CB57-A9C9-4B2E-806D-4C4D270C0966 Q30358337-43319EDF-2710-4182-A663-613D154941CF Q30423589-55D90A5F-DD7B-461D-99C7-A519B7214808 Q30570005-71C289CF-475A-43D5-B877-E787403432E3 Q30577625-76034C32-DA24-4C4B-B995-6CB25863F98B Q30586896-6B3CF468-E80B-4492-B58E-18728544CCCC Q30597329-77C5140C-6861-4713-AD99-78D6186377DD Q30611520-863DD80A-FC2E-4786-925A-7B5CE5D524F4 Q30736054-E018CBE4-F39F-4FE1-82BB-1CD6C8F6625B Q30828496-F45EF495-4C60-4894-8FB1-0409A7E476CB Q30833019-F95D70C8-4BDF-4931-BBE3-622BC552A245 Q31008758-BFC064E4-6A16-416C-B57F-9C7F02B6624C Q31080551-AD49A2A2-C3BB-41AF-BC2E-97E129BA6D07 Q31096478-63D8A734-D3F1-4FF9-AAD7-DE97FF9BFA57 Q31097087-D0EB8F87-3436-4ACD-9A79-BEB9BF87B8A4 Q31097119-206426E5-DF07-4361-818D-DC591A82FFB2 Q31145409-79C83911-0B36-40F8-B3B0-D8E620C9316F Q31155092-24481D6D-4867-41B2-90E9-804D034C536B Q31155412-9370F9BB-4844-42A3-BEFD-39A256468912 Q33562433-92D830C5-4177-43C1-BA65-2F610C448D9E Q33562458-AE9C5186-8F25-4D19-8DC9-259A72A65FB2 Q33672820-D96254A1-0E25-4A50-B34D-0127FDF073E4

P2860

Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines.

http://www.wikidata.org/entity/Q36810589

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Diagnostic criteria for mild c ...... Society Task Force guidelines.

@ast

Diagnostic criteria for mild c ...... Society Task Force guidelines.

@en

type

label

Diagnostic criteria for mild c ...... Society Task Force guidelines.

@ast

Diagnostic criteria for mild c ...... Society Task Force guidelines.

@en

prefLabel

Diagnostic criteria for mild c ...... Society Task Force guidelines.

@ast

Diagnostic criteria for mild c ...... Society Task Force guidelines.

@en

P1433

Q36810589-72596178-FDCF-4443-9F67-2B3E22C8DDCF

P1476

Q36810589-889996C6-12BE-4371-89AD-E4D2B4F0F669

P2093

Q36810589-022712E6-133C-4331-B92C-A59457683910

Q36810589-0277B8A0-0E15-4FDB-93A1-B34BA102FEF3

Q36810589-0F6197DE-14D8-487A-87C4-8AA17E5D20AC

Q36810589-244B2236-02C3-44CD-B484-885200C35160

Q36810589-63F71BC5-37B4-45F6-A412-F569AF5CB3DC

Q36810589-8FF0EA00-43FC-4E8E-AF5D-B0001993437A

Q36810589-A903E4EF-7D60-4680-85D9-2E1FB5C6D034

Q36810589-E9BA75FC-9191-4C6A-BEE7-34DBEDA0E5E5

P2860

Q36810589-040DAA09-5B6F-4D2B-ABB3-929A5167819F

Q36810589-07DD9A60-3958-4D03-9114-15AFEEABD985

Q36810589-07F1D2CC-2B55-4141-9C43-C034E7198551

Q36810589-0E3DFED2-AE69-4AB2-A067-DC4491CD5577

Q36810589-0E5561A4-08E2-4982-AC17-1BE049919168

Q36810589-121D8275-B932-4797-BED5-A1E47AE6A4B9

Q36810589-138FD6BB-08E7-4996-8BDC-4C2C17125F28

Q36810589-2C835C41-331E-43EB-9E19-E2F54E68B74D

Q36810589-2F2758EA-3F7B-4886-B650-FDF30FC9A97E

Q36810589-392D68E4-8EB2-48A8-8E76-E91A90136C3D

P304

Q36810589-7E2B92B8-D405-43E2-940B-34761A2BEFCA

P31

Q36810589-548400A6-3180-4C13-BBD3-CA4CF233FF5E

P356

Q36810589-9DC0A4AB-97F5-4CB3-BE84-465D1A5752B2

P407

Q36810589-92E18F56-6F05-411E-A91B-9EA0EA98BFA8

P433

Q36810589-669A3C43-0486-4133-A0BA-1B574B53D8BF

P478

Q36810589-E08FCD5E-81B9-4092-95B4-C77FEFBDDB28

P50

Q36810589-6027E1A4-9032-4900-8E77-700A230D2D1E

Q36810589-8873624B-3B17-4C15-8BB4-C62808EA9520

Q36810589-8D926F79-46DC-48E4-9B53-451FBF46D398

Q36810589-97620E2A-37CF-4146-8AFB-136BC5BEADE3

Q36810589-A706AA41-7572-4830-9F59-794A96548777

Q36810589-C546C10D-A1CE-4FF2-B416-4DD6D9CEA097

Q36810589-DD041410-EF3A-4462-96A7-E1FEA6817494

Q36810589-FD3FD4D7-D403-46CD-A5F5-DF5A344E67A9

P577

Q36810589-80C9B5EF-6293-4E6C-975B-36D506BE2ADD

P5875

Q36810589-5201025F-BD27-4051-9BA3-B028CA61F234

P698

Q36810589-A5EE3487-9EDF-46C9-A924-C21847A7031F

P921

Q36810589-672727E4-17B6-4ECB-A8E8-AEDD6899D688

P932

Q36810589-7E5B07A9-25C4-4264-866E-244E3D8525E5

P356

P1433

Movement Disorders

P1476

Diagnostic criteria for mild c ...... Society Task Force guidelines.

@en

P2093

Alexander I Tröster

http://www.w3.org/2001/XMLSchema#string

Ben A Schmand

http://www.w3.org/2001/XMLSchema#string

Caroline H Williams-Gray

http://www.w3.org/2001/XMLSchema#string

David J Burn

http://www.w3.org/2001/XMLSchema#string

Jennifer G Goldman

http://www.w3.org/2001/XMLSchema#string

Karen Marder

http://www.w3.org/2001/XMLSchema#string

Maria C Rodriguez-Oroz

http://www.w3.org/2001/XMLSchema#string

Murat Emre

http://www.w3.org/2001/XMLSchema#string

P2860

Cognitive dysfunction and dementia in Parkinson disease

The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

Mild cognitive impairment as a diagnostic entity

Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease

The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease

Use of latent variable modeling to delineate psychiatric and cognitive profiles in Parkinson disease.

Complex activities of daily living vary by mild cognitive impairment subtype.

Normative data for the Montreal Cognitive Assessment (MoCA) in a population-based sample.

The MoCA: well-suited screen for cognitive impairment in Parkinson disease.

CSF amyloid {beta} 1-42 predicts cognitive decline in Parkinson disease.

P304

349-356

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/MDS.24893

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P50

Brit Mollenhauer

Ronald C. Petersen

Roger A. Barker

Charles H Adler

Daniel Weintraub

Jaime Kulisevsky

P577

2012-01-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221775541

http://www.w3.org/2001/XMLSchema#string

P698

22275317

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

P932

3641655

http://www.w3.org/2001/XMLSchema#string